Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 6/20 | 0.35 |
| ▸ | HTR2A | P28223 | 5/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6216628 | 0.86 | MAPK1 (0.36) | MAPK1KMT2AAHRHTR2CHTR2A | |
| SCHEMBL6218592 | 0.84 | SLC6A2 (0.39) | MAPK1KMT2AHTR2CHTR2AKCNH2 | |
| SCHEMBL6216964 | 0.84 | MAPK1 (0.34) | MAPK1KMT2AAHRHTR2CHTR2A | |
| SCHEMBL6217869 | 0.82 | AHR (0.35) | MAPK1KMT2AAHRHTR2CHTR2A | |
| SCHEMBL905993 | 0.80 | MAPK1 (0.40) | MAPK1KMT2AAHRHTR2CHTR2A | |
| SCHEMBL12029844 | 0.80 | MAPK1 (0.40) | MAPK1KMT2AAHRHTR2CHTR2A | |
| SCHEMBL6217518 | 0.80 | MAPK1 (0.40) | MAPK1KMT2AAHRHTR2CHTR2A | |
| SCHEMBL6670263 | 0.76 | MAPK1 (0.35) | MAPK1KMT2AAHRHTR2CHTR2A | |
| SCHEMBL15800591 | 0.71 | SIRT2 (0.36) | MAPK1KMT2AAHRHTR2C | |
| SCHEMBL8654057 | 0.69 | SIRT2 (0.43) | HTR2CHTR2AKCNH2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414819-B1 | THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES | PHARMACIA & UPJOHN CO LLC (US) | 2005-10-12 | — | — | EP | claimed |
| US-6849640-B2 | Therapeutic 1H-pyrido [4,3-b] indoles | PHARMACIA & UPJOHN COMPANY (US) | 2005-02-01 | — | — | US | claimed |
| US-20030060464-A1 | Therapeutic 1H-pyrido [ 4, 3-b ] indoles | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | claimed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| EP-1414819-B1 | THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES | PHARMACIA & UPJOHN CO LLC (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6849640-B2 | Therapeutic 1H-pyrido [4,3-b] indoles | PHARMACIA & UPJOHN COMPANY (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| US-20030060464-A1 | Therapeutic 1H-pyrido [ 4, 3-b ] indoles | PHARMACIA & UPJOHN COMPANY | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | MAPK1 3719/4885KMT2A 2378/4885AHR 571/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | MAPK1 3719/4885KMT2A 2378/4885AHR 571/4885 |
| US-20030060464-A1 | Therapeutic 1H-pyrido [ 4, 3-b ] indoles | HTR3B, HTR4, HTR3C | MAPK1 3730/4885KMT2A 4111/4885AHR 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.